$0.00
(Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-20 Mln
-
ROE
-3.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
14,459,700
10 Years Aggregate
CFO
$-144.75 Mln
EBITDA
$-168.15 Mln
Net Profit
$-238.29 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
| -93.7 | 38.2 | -97.0 | -98.1 | -82.7 | -77.8 | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
| -93.6 | 14.0 | 54.2 | -75.9 | -61.9 | -65.1 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
9 Meters Biopharma (NMTR)
|
0.0 | 1.0 | 0.0 | -49.8 | -- | -- | -- | 1.6 |
| 82.9 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 73.8 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 56.1 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 347.0 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 534.5 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 587.5 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 | |
| 334.6 | 9,822.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.4 |
Shareholding Pattern
View DetailsAbout 9 Meters Biopharma (NMTR)
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate... is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. Read more
-
Pres, CEO & Director
Mr. John Temperato
-
Pres, CEO & Director
Mr. John Temperato
-
Headquarters
Raleigh, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for 9 Meters Biopharma (NMTR)
What is the current share price of 9 Meters Biopharma Inc (NMTR) Today?
The share price of 9 Meters Biopharma Inc (NMTR) is $0.02 (NASDAQ) as of 26-Sep-2023 09:30 EDT. 9 Meters Biopharma Inc (NMTR) has given a return of -82.67% in the last 3 years.
What is the current PB & PE ratio of 9 Meters Biopharma Inc (NMTR)?
Since, TTM earnings of 9 Meters Biopharma Inc (NMTR) is negative, P/E ratio is not available.
The P/B ratio of 9 Meters Biopharma Inc (NMTR) is 1.59 times as on 26-Sep-2023, a 70 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of 9 Meters Biopharma Inc (NMTR)?
The 52-week high and low of 9 Meters Biopharma Inc (NMTR) are Rs -- and Rs -- as of 12-Sep-2026.
What is the market cap of 9 Meters Biopharma Inc (NMTR)?
9 Meters Biopharma Inc (NMTR) has a market capitalisation of $ 1 Mln as on 26-Sep-2023. As per SEBI classification, it is a company.
Should I invest in 9 Meters Biopharma Inc (NMTR)?
Before investing in 9 Meters Biopharma Inc (NMTR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.